Aytu Biopharma, Inc. AYTU
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Aytu Biopharma, Inc. (AYTU) is a healthcare company listed in the US with a market value of about $19M. In fiscal year 2026 it had revenue of $58M and net income of -$14M, a net margin of -24.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 5.9, 5-year revenue growth of -3% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.
About Aytu Biopharma
Aytu Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $261782 in 2015 to $58M in 2026, growth of about 63.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 269% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/FCF below 20
- More cash than debt, or low debt to equity
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58M | $66M | $65M | $107M | $97M | $66M | $28M | $7M | $4M | $3M |
| Net income | -$14M | -$14M | -$16M | -$17M | -$109M | -$58M | -$14M | -$27M | -$10M | -$23M |
| Free cash flow | $3M | -$2M | -$2M | — | -$29M | -$28M | -$28M | -$14M | -$16M | -$14M |
| EPS (diluted) | $-1.16 | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-69.60 | $-60.20 | $-696.00 | $-3062.00 | $-9660.00 |
| Net margin | -24.8% | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -370.6% | -278.4% | -698.7% |
| ROIC | -13.9% | -18.8% | -3.0% | -30.3% | -167.1% | -29.4% | -21.8% | -187.8% | -115.9% | -397.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Aytu Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Aytu Biopharma pay a dividend?
Not currently.
Is Aytu Biopharma a good stock to buy?
We do not give buy or sell advice. Aytu Biopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.